Totality of the evidence at work: The first US biosimilar

被引：34

作者：

Holzmann, J. ^{[1
]}

Balser, S. ^{[2
]}

Windisch, J. ^{[1
]}

机构：

[1] Sandoz Biopharmaceut, Biopharmaceut Dev, A-6250 Kundl, Austria

[2] HEXAL AG, Clin Dev Biopharmaceut, Oberhaching, Germany

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2016年 / 16卷 / 02期

关键词：

Biosimilar; filgrastim; filgrastim-sndz; G-CSF; Neupogen; neutropenia; Zarxio; FILGRASTIM; CHEMOTHERAPY; NEUTROPENIA;

D O I：

10.1517/14712598.2016.1128410

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

On March 6(th) 2015, the Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio) as the first biosimilar in the United States (US) for all indications of the reference product. Filgrastim-sndz is a biosimilar of Amgen's Neupogen and is mainly used to treat neutropenia in cancer patients receiving chemotherapy. This article presents a summary of the analytical and clinical studies submitted by Sandoz and describes how the information was integrated to provide the totality of the evidence' leading to the approval of the biosimilar.

引用

页码：137 / 142

页数：6

共 50 条

[21] First reviews are published that are based on the "totality of the evidence"
Kmietowicz, Zosia
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
[22] Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17
Ombretta Viapiana
Soohyun Lee
SangWook Yoon
Bruno Fautrel
[J]. Clinical Drug Investigation, 2022, 42 : 103 - 112
[23] Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17
Viapiana, Ombretta
Lee, Soohyun
Yoon, SangWook
Fautrel, Bruno
[J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (02) : 103 - 112
[24] A TOTALITY-OF-THE-EVIDENCE APPROACH TO THE DEVELOPMENT OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR
McCamish, M.
DaSilva, A.
Mayer, R. Ernst
Fritsch, C.
Schiestl, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1010 - 1010
[25] First biosimilar antibody nears US approval
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2016, 15 : 151 - 151
[26] First biosimilar antibody nears US approval
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (03) : 151 - 151
[27] First US biosimilar edges towards market
Melanie Senior
[J]. Nature Biotechnology, 2015, 33 : 222 - 223
[28] Novartis Launches First US 'Biosimilar' Drug
不详
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2015, 14 (10) : 1176 - 1176
[29] First US biosimilar edges towards market
Senior, Melanie
[J]. NATURE BIOTECHNOLOGY, 2015, 33 (03) : 222 - 223
[30] SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation
Peeters, Marc
Lipp, Hans-Peter
Park, Minjeong
Yoon, Ye Chan
Arnold, Dirk
[J]. FUTURE ONCOLOGY, 2023, 19 (06) : 427 - 450

← 1 2 3 4 5 →